|
Pooled estimates
|
Pooling model
|
Number of studies, haplo-HSCT + MSCs/haplo-HSCT alone
|
haplo-HSCT + MSCs (95% CI)
|
haplo-HSCT alone (95% CI)
|
OR (95% CI)
|
p value
|
|---|
|
aGVHD
|
Fixed/random
|
7/9
|
56.0% (48.6%, 63.5%)
|
47.2% (29.0%, 65.4%)
|
1.43 (0.91–2.25)
|
0.123
|
|
Grade II–IV aGVHD
|
Fixed/random
|
8/20
|
29.8% (24.1%, 35.5%)
|
30.6% (26.6%,34.6%)
|
0.97 (0.70–1.32)
|
0.889
|
|
cGVHD
|
Fixed/random
|
8/18
|
25.4% (19.8%, 31.0%)
|
30.0% (23.3%,36.6%)
|
0.79 (0.56–1.11)
|
0.187
|
|
2-year OS
|
Fixed/fixed
|
8/12
|
84.9% (80.4%, 89.3%)
|
85.2% (81.6%,88.8%)
|
0.98 (0.60–1.61)
|
1.000
|
|
Engraftment rate
|
Fixed/fixed
|
8/17
|
98.9% (96.4%, 100.0%)
|
98.6% (96.5%,99.8%)
|
1.02 (0.66–1.54)
|
1.000
|
|
CMV infection rate
|
Random/random
|
5/10
|
52.4% (31.6–73.1%)
|
64.1% (52.9–75.2%)
|
0.61 (0.40–1.92)
|
0.018
|
- Abbreviations: GVHD graft-versus-host disease, aGVHD acute GVHD, cGVHD chronic GVHD, MSCs mesenchymal stromal cells, haplo-HSCT haplo-identical hematopoietic stem cell transplantation, OR odds ratio, OS overall survival, CI confidence interval, CMV cytomegalovirus
